Foster Dykema Cabot & Co’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $910K | Buy |
8,836
+750
| +9% | +$80.8K | 0.11% | 40 |
|
|
2023
Q2 | $933K | Buy |
8,086
+454
| +6% | +$51.5K | 0.11% | 41 |
|
|
2023
Q1 | $812K | Buy |
7,632
+151
| +2% | +$16.3K | 0.1% | 44 |
|
|
2022
Q4 | $830K | Sell |
7,481
-1,062
| -12% | -$109K | 0.12% | 43 |
|
|
2022
Q3 | $736K | Hold |
8,543
| – | – | 0.09% | 46 |
|
|
2022
Q2 | $779K | Hold |
8,543
| – | – | 0.1% | 43 |
|
|
2022
Q1 | $701K | Buy |
8,543
+200
| +2% | +$15.8K | 0.08% | 51 |
|
|
2021
Q4 | $639K | Hold |
8,343
| – | – | 0.07% | 57 |
|
|
2021
Q3 | $627K | Sell |
8,343
-153
| -2% | -$11.6K | 0.08% | 59 |
|
|
2021
Q2 | $661K | Sell |
8,496
-408
| -5% | -$30.3K | 0.08% | 57 |
|
|
2021
Q1 | $655K | Sell |
8,904
-13,169
| -60% | -$971K | 0.09% | 53 |
|
|
2020
Q4 | $1.72M | Buy |
22,073
+153
| +0.7% | +$11.7K | 0.24% | 40 |
|
|
2020
Q3 | $1.74M | Sell |
21,920
-54
| -0.2% | -$4.23K | 0.28% | 34 |
|
|
2020
Q2 | $1.62M | Buy |
21,974
+99
| +0.5% | +$7.45K | 0.29% | 33 |
|
|
2020
Q1 | $1.61M | Buy |
21,875
+14,986
| +218% | +$1.18M | 0.31% | 30 |
|
|
2019
Q4 | $598K | Hold |
6,889
| – | – | 0.08% | 58 |
|
|
2019
Q3 | $553K | Hold |
6,889
| – | – | 0.08% | 68 |
|
|
2019
Q2 | $551K | Hold |
6,889
| – | – | 0.08% | 67 |
|
|
2019
Q1 | $547K | Buy |
6,889
+192
| +3% | +$14.4K | 0.09% | 65 |
|
|
2018
Q4 | $488K | Hold |
6,697
| – | – | 0.09% | 66 |
|
|
2018
Q3 | $453K | Hold |
6,697
| – | – | 0.07% | 73 |
|
|
2018
Q2 | $414K | Sell |
6,697
-68,862
| -91% | -$3.88M | 0.07% | 74 |
|
|
2018
Q1 | $3.93M | Buy |
75,559
+3,178
| +4% | +$172K | 0.67% | 25 |
|
|
2017
Q4 | $3.89M | Sell |
72,381
-6,056
| -8% | -$336K | 0.65% | 25 |
|
|
2017
Q3 | $4.79M | Sell |
78,437
-100
| -0.1% | -$6.06K | 0.84% | 21 |
|
|
2017
Q2 | $4.8M | Sell |
78,537
-3,290
| -4% | -$200K | 0.86% | 20 |
|
|
2017
Q1 | $4.96M | Buy |
81,827
+1,219
| +2% | +$74K | 0.9% | 19 |
|
|
2016
Q4 | $4.53M | Buy |
80,608
+287
| +0.4% | +$16.8K | 0.85% | 22 |
|
|
2016
Q3 | $4.78M | Buy |
80,321
+571
| +0.7% | +$33.4K | 1.04% | 20 |
|
|
2016
Q2 | $4.38M | Buy |
79,750
+1,499
| +2% | +$79.8K | 1.02% | 22 |
|
|
2016
Q1 | $3.95M | Buy |
78,251
+69,561
| +800% | +$3.41M | 0.96% | 25 |
|
|
2015
Q4 | $438K | Sell |
8,690
-524
| -6% | -$26.4K | 0.11% | 66 |
|
|
2015
Q3 | $434K | Hold |
9,214
| – | – | 0.11% | 59 |
|
|
2015
Q2 | $501K | Sell |
9,214
-723
| -7% | -$40.5K | 0.13% | 55 |
|
|
2015
Q1 | $545K | Hold |
9,937
| – | – | 0.13% | 54 |
|
|
2014
Q4 | $538K | Hold |
9,937
| – | – | 0.13% | 55 |
|
|
2014
Q3 | $562K | Hold |
9,937
| – | – | 0.14% | 50 |
|
|
2014
Q2 | $549K | Buy |
9,937
+1,142
| +13% | +$62.3K | 0.13% | 54 |
|
|
2014
Q1 | $476K | Hold |
8,795
| – | – | 0.12% | 54 |
|
|
2013
Q4 | $420K | Hold |
8,795
| – | – | 0.11% | 62 |
|
|
2013
Q3 | $400K | Hold |
8,795
| – | – | 0.12% | 64 |
|
|
2013
Q2 | $390K | Buy |
+8,795
| New | +$393K | 0.12% | 62 |
|
Other funds holding MRK
Foster Dykema Cabot & Co's MRK Position: Q3 2023 in Review
Foster Dykema Cabot & Co increased its Merck (MRK) stake by 9.3% in Q3 2023, buying an estimated $80.8K and bringing the position to 8,836 shares worth $910K. The position accounts for 0.11% of the portfolio, ranked #40.
Foster Dykema Cabot & Co first reported a position in MRK in Q2 2013 and has held it in 42 quarters since. The position peaked at $4.96M in Q1 2017. 3,213 funds tracked by Wall St. Rank hold MRK as of Q3 2023.
- Foster Dykema Cabot & Co held 8,836 shares of Merck worth $910K as of Q3 2023.
- Foster Dykema Cabot & Co bought 750 Merck shares in Q3 2023, an estimated $80.8K.
- Merck made up 0.11% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #40 holding.
- Foster Dykema Cabot & Co first reported a position in Merck in Q2 2013 and has held it in 42 quarters since.
- Foster Dykema Cabot & Co's Merck position peaked at $4.96M in Q1 2017.
- 3,213 funds tracked by Wall St. Rank held Merck as of Q3 2023.
Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.